Holding a Master's in Biopharmaceutical Regulatory Affairs, I possess a rare dual fluency — deeply conversant in both the scientific language of cell biology and the regulatory architecture that governs therapeutic development. This expertise is not merely administrative; it is strategically essential.
Navigating the FDA's Center for Biologics Evaluation and Research (CBER), EMA pathways, and international equivalents requires precision and foresight. I work to ensure that innovative therapies are not only scientifically sound but also positioned for successful regulatory review and approval — accelerating the path from bench to bedside.
Scientific excellence means little if transformative therapies remain out of reach for the patients who need them most. Beyond the laboratory, I am deeply committed to addressing unmet medical needs through two critical pathways: compassionate use requests and facilitated medical tourism.
Compassionate use programs — also known as expanded access — allow patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials. Navigating these regulatory pathways requires both scientific credibility and regulatory acumen, skills I bring to bear on behalf of patients who have exhausted conventional options.
Through medical tourism facilitation, I connect patients with internationally available regenerative treatments that may not yet be accessible in their home countries, ensuring they receive care that is both scientifically sound and ethically administered.
A Canadian/Hungarian/American researcher based in Bellingham, WA — bridging biochemistry, AI, and transformative cell therapies to redefine what's possible in modern medicine.